Dermatology News

• Alert EU Backs Drug to Relieve Itching in Alagille Syndrome The European Medicines Agency said there were exceptional circumstances for approving Kayfanda to treat pruritus in patients with the rare genetic disorder.
  Medscape Medical News, July 26, 2024
• Alert Anzupgo Approved in Europe for Severe Hand Eczema The drug downregulates immune and inflammatory responses in cells linked to the disease pathology.
  Medscape Medical News, July 26, 2024
• Alert FDA Approves JAK Inhibitor for Alopecia Areata The pivotal phase 3 trials enrolled 1223 adults in the United States, Canada, and Europe.
  Medscape Medical News, July 26, 2024
• Tirbanibulin 1% Safe in Extensive Actinic Keratosis The safety and tolerability of tirbanibulin 1% in patients with actinic keratosis over a larger treatment field was confirmed in a phase 3 study.
  Medscape Medical News, July 26, 2024
• 'Doesn't Fit Anything I Trained for': Treating Chronic Lyme Researchers, clinicians, and patient advocates at a national meeting weighed in on efforts needed to accelerate research on treatments for chronic illness associated with Lyme disease.
  Medscape Medical News, July 26, 2024
• A Woman, a Tuna Steak, and Allergy-like Symptoms Scombroid poisoning resembles an allergic reaction and occurs after eating fish contaminated with histamine.
  Medscape News UK, July 26, 2024
• Newer Shingles Vaccine Tied to Lower Dementia Risk A new study showed a newer recombinant shingles vaccine was linked to a 164-day delay in dementia diagnosis in older adults compared to an older live shingles vaccine.
  Medscape Medical News, July 25, 2024
• EULAR 2024 Taper, Dose Down, Discontinue: Striving for Less Steroid Use Now in the 75th year since the first presentation on the clinical use of glucocorticoids, what consensus has been reached in sparing their use to avoid their many potential adverse effects?
  Medscape Medical News, July 25, 2024
• GRAPPA 2024 MACE Risk Similar Among Biologics for Psoriasis, PsA A retrospective analysis shows no difference in major adverse cardiovascular events (MACE) between TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/IL-23 inhibitors.
  Medscape Medical News, July 25, 2024
• GRAPPA 2024 Adverse Events Differ Between Two Second-Line Psoriasis Rxs Apremilast and deucravacitinib, oral small-molecule drugs approved for treating psoriasis, were linked to different adverse events, and adverse event profiles differed between men and women.
  Medscape Medical News, July 25, 2024
• EULAR 2024 Breaking Rheumatology's Reliance on Steroids: New Strategies Selective GC receptor agonists and modulators and GC plus hydroxysteroid dehydrogenase inhibitor combination therapy are some of the approaches under consideration.
  Medscape Medical News, July 25, 2024
• GRAPPA 2024 MHC-1-Opathies Linked to Ancient Retrovirus Infections Psoriasis is one of several autoimmune diseases linked to variations in MHC-1 that may have protected our ancestors from retroviruses.
  Medscape Medical News, July 24, 2024
• Delgocitinib Effective for Hand Eczema in Phase 3 Studies Topical delgocitinib was effective and well tolerated in patients with chronic hand eczema with no safety concerns.
  Medscape Medical News, July 23, 2024
• GRAPPA 2024 Psoriatic Arthritis Treatment Failure Tied to Key Factors Comorbidities, disease characteristics, and socioeconomic factors were linked to failure to respond to disease-modifying antirheumatic drugs in patients with psoriatic arthritis.
  Medscape Medical News, July 23, 2024
• SPD 2024 Pediatric Rheumatology/Dermatology Clinic: Benefits Explored Team members participate in a preclinic conference to review patient data and images, discuss relevant literature, and develop an approach to each patient.
  Medscape Medical News, July 23, 2024
• SPD 2024 Underserved Families Sound Off on Pediatric Derm Access The findings are based on in-depth interviews with parents and/or guardians of children who received care at a pediatric dermatology clinic.
  Medscape Medical News, July 22, 2024
• SPD 2024 Munchausen Syndrome by Proxy: Be Aware of Cutaneous Signs The cutaneous manifestations of Munchausen syndrome by proxy are complex, but pediatric dermatologists can play an important role in their identification.
  Medscape Medical News, July 22, 2024
• SPD 2024 Colchicine Effective for Pediatric Aphthous Ulcers The findings come from a retrospective review of Mayo Clinic patients.
  Medscape Medical News, July 22, 2024
• GRAPPA 2024 MSK Symptoms, Psoriasis: Dermatologists or Rheumatologists? A dermatologist argues for a role to prevent psoriatic arthritis, but rheumatologist favors experience in diagnosis.
  Medscape Medical News, July 19, 2024
• SPD 2024 Consider Risks for Some Topical Ingredients in Children In pediatric dermatology, the list of potentially toxic products includes topical analgesics such as Castellani paint used for skin infections and alcohols used for umbilical care in newborns.
  Medscape Medical News, July 18, 2024